Clinical Trials Browser

Phase 2 × Lymphoma, Mantle-Cell × Lisaftoclax × Clear all

NCT07272499 2025-12-09

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Phase 2 Recruiting

Lymphoma, Mantle-Cell